Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Eledon Pharmaceuticals, Inc. | d291766dex991.htm |
| EX-32.1 - EXHIBIT 32.1 - Eledon Pharmaceuticals, Inc. | d291766dex321.htm |
| EX-31.2 - EXHIBIT 31.2 - Eledon Pharmaceuticals, Inc. | d291766dex312.htm |
| EX-31.1 - EXHIBIT 31.1 - Eledon Pharmaceuticals, Inc. | d291766dex311.htm |
| EX-23.1 - EXHIBIT 23.1 - Eledon Pharmaceuticals, Inc. | d291766dex231.htm |
| EX-12.1 - EXHIBIT 12.1 - Eledon Pharmaceuticals, Inc. | d291766dex121.htm |
| EX-2.1 - EX-2.1 - Eledon Pharmaceuticals, Inc. | d291766dex21.htm |
| 10-K - FORM 10-K - Eledon Pharmaceuticals, Inc. | d291766d10k.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Tokai Pharmaceuticals, Inc. (the “Company”) for the fiscal year ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, John S. McBride, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
| (1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: March 3, 2017 | By: | /s/ John S. McBride | ||
| John S. McBride | ||||
| Chief Financial Officer and Chief Operating Officer | ||||
| (Principal Financial and Accounting Officer) |